DEVELOPMENT OF NANOLIPOSOMES FOR THE TREATMENT OF BRAF V600E MUTATED PARENT AND VEMURAFENIB-RESISTANT MELANOMA by Fu, Yige
St. John's University 
St. John's Scholar 
Theses and Dissertations 
2021 
DEVELOPMENT OF NANOLIPOSOMES FOR THE TREATMENT OF 
BRAF V600E MUTATED PARENT AND VEMURAFENIB-RESISTANT 
MELANOMA 
Yige Fu 
Follow this and additional works at: https://scholar.stjohns.edu/theses_dissertations 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
DEVELOPMENT OF NANOLIPOSOMES FOR THE TREATMENT OF BRAF 
V600E MUTATED PARENT AND VEMURAFENIB-RESISTANT MELANOMA 
A dissertation submitted in partial fulfillment of the 
requirements for the degree of 
DOCTOR OF PHILOSOPHY 
to the faculty of the 
DEPARTMENT OF GRADUATE DIVISION 
of
          COLLEGE PHARMACY AND HEALTH SCIENCES 
at 




Date Submitted: ____________________    Date Approved: ___________________ 
_________________________________    ________________________________ 











DEVELOPMENT OF NANOLIPOSOMES FOR THE TREATMENT OF BRAF 
V600E MUTATED PARENT AND VEMURAFENIB-RESISTANT MELANOMA 
 
YIGE FU  
 
 
Melanoma is one of the most aggressive and deadliest types of skin cancer. Currently, 
off-target toxicities and the rapid resistance development of metastatic melanoma mainly 
restrict the efficiency of the treatments. This thesis presents efforts towards developing 
liposomes to address current problems of BRAF-mutant metastatic melanoma. 
EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF 
V600E Mutated Parent and Resistant Melanoma 
In order to address off-target toxicities of the targeted therapy of MEK inhibitor 
trametinib (TMB), we developed a physically stable EphrinA1-mimicking peptide (YSA) 
anchored TMB-loaded PEGylated nanoliposomes (YTPLs). The YTPLs were evaluated 
in BRAFV600E-mutated parent cell lines (A375 and SK-MEL-28) and vemurafenib-
resistant cell lines (A375R and SK-MEL-28R). A differential scanning calorimetry (DSC) 
study confirmed that TMB was retained in a solubilized state within the lipid bilayers. No 
burst release was observed of TMB in 24 h and negligible hemolysis was observed at 
therapeutic concentrations of TMB. YTPL showed higher intracellular uptake in parental 
cell lines compared to vemurafenib-resistant cell lines. Western blot analysis and a 
cytotoxicity study with the EphA2 inhibitor confirmed a reduction in EphA2 expression 
in resistant cell lines. Thus, YTPLs can be useful for metastatic melanoma-specific 
delivery of TMB. 
 
 
Development of BRD4 PROTAC and anti-fibrotic agent co-loaded PEGylated 
Nanoliposome for BRAF inhibitor resistant Melanoma 
In the present study, we proposed a new treatment strategy for the treatment of 
vemurafenib-resistant melanoma by targeting to both cancer cells and tumor stroma. A 
BRD4 proteolysis targeting chimera (ARV-825) and nintedanib co-loaded PEGylated 
nanoliposomes (ARNIPL) were developed in a synergistic cytotoxic ratio against 
vemurafenib-resistant melanoma. Both the molecules have extremely poor aqueous 
solubility. Citric acid was used to improve the loading of both the molecules in ARNIPL. 
ARNIPL with mean particle size 111.1 ± 6.55 nm exhibited more than 90% 
encapsulation efficiency (EE) for both the drugs and was found to be physically stable for 
a month. Both the molecules and ARNIPL showed significantly higher cytotoxicity, 
apoptosis and downregulation of target proteins BRD4 and c-Myc in vemurafenib-
resistant cell line (A375R). Vasculogenic mimicry and clonogenic potential of A375R 
were significantly inhibited by ARNIPL. Tumor growth inhibition in 3D spheroid of 
A375R and 3D spheroid of co-culture of A375R+Dermal fibroblasts model with 
reduction of TGF-β1 was observed with ARNIPL treatment. Therefore, ARNIPL could 
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1  Introduction 
1.1  Melanoma 
Human melanomas are the malignant tumors that develops when melanocytes (pigment-
producing cells) begin to grow out of control as shown in Figure 1. Even though 
melanoma is much less common than basal cell and squamous cell skin cancers, it is 
more threatening since it’s more likely to spread to other parts of the body if not found 
and treated in the early stage. Melanoma is the fifth most common cancer among men 
and the sixth most common cancer among women. The approximates of melanoma in the 
United States is about 100,350 new cases (60,190 men and 40,160 women) to be 
diagnosed and 6,850 people expected to die of melanoma in 2020 [1]. Melanomas are 
normally form in the skin though it can also be found in other parts of your body like the 
eyes, mouth, genitals, and anal area with less chances. Approximately 80% of the 
melanomas are diagnosed at localized stages and one-third of those early-staged patients 
tend to develop metastatic melanoma. Even though early detection of melanoma is 
curable by surgical resection, due to poor prognosis of metastasis, five-year survival rates 
dropping down from 98% to 17% [2]. There are many risk factors that can enhance the 
chance of developing melanoma skin cancers. Exposure to ultraviolet (UV) rays either 
come from too much sun exposure or from man-made sources like indoor tanning beds 
and sun lamps is the main risk factor of melanoma development. Additionally, other risk 
factors such as moles, fair skin, weakened immune system, family history of melanoma, 
and age may also raise the risk of melanoma growth. American Cancer Society suggested 
three prevention aspects including reducing exposure to UV radiation, watching for 
abnormal moles, and avoiding weaken immune systems. Cutaneous melanoma on non-
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glabrous skin is usually classified into chronic sun-induced damage (CSD melanomas) or 
those not associated with solar damage (non-CSD melanomas). CSD melanomas 
normally occurs in in elder individuals and have a high mutation burden related to 
neurofibromin 1 (NF1), NRAS, BRAFnonV600E or KIT mutations in approximately 20%, 
while non-CSD melanomas associated with a moderate mutation burden and associated 
with frequent BRAFV600E mutations and no KIT mutations [3,4]. Clinically, more than 
90% of melanomas diagnosed are cutaneous and normally only one mutation can be 
observed in a patient. Genetic analysis of melanoma has allowed us to identify gene 
mutation in metastatic melanoma. BRAF mutation is the most frequent genetic 
abnormalities (approximately 40~60%) among all the mutations in metastatic melanoma 
and BRAFV600E is the most common mutation (more than 97% of BRAF mutations), 
where valine is substituted by glutamic acid at codon 600 of the BRAF gene [5,6]. BRAF 
protein is a serine/threonine protein kinase of 766 amino acids and plays a significant role 
in mitogen-activated protein kinase (MAPK) pathway, which involved in the transduction 
of extracellular signals to the nucleus and is important to cell proliferation, differentiation, 


























1.2  Treatment approaches 
There are five stages of melanoma depending on the thickness of the tumor and if the 
melanoma spread or not. Current therapeutic options include surgery, radiation therapy, 
chemotherapy, immunotherapy, and targeted therapy. The type of treatment(s) depends 
on many factors, such as the stage and location of the melanoma, patient’s overall health, 
the risk of the cancer returning after treatment, and if the cancer cells have certain gene 
changes [9,10].   not effective for melanoma since it is normally refractory to conventional 
chemotherapeutic agents. Dacarbazine was the only FDA approved chemotherapeutic 
agent for the treatment of metastatic melanoma till 2010. However, dacarbazine has mere 
15-20 % overall response rate and was showed enhanced tumor growth and metastasis in 
vivo [11]. Chemo drug is usually not used as the first choice since immunotherapy and 
targeted drugs have become available. Immunotherapy is designed to stimulate immune 
system by targeting to checkpoint protein on immune cells, which allows to kill 
melanoma cells more effectively. The response of immunotherapy depends on the 
presence of protein on cells. The first agents of FDA-approved immunotherapies in 
unresectable cutaneous melanomas including anti-PD-1 drugs (nivolumab, 
pembrolizumab) and anti-CTLA-4 antibody ipilimumab. The FDA approved the 
immunotherapy combination of ipilimumab and nivolumab for the treatment of 
unresectable stage III or stage IV melanoma in 2015 and showed increasing response and 
survival rate. However, it also raises the incidence of adverse effects [12,13] Other 
therapeutic methods based on immunological response are cytokines (interferon-alfa 
(IFN-α) and interleukin-2(IL-2)), are used for advanced melanomas in a way that can 
boost immune system. Adoptive cell therapy or FDA-approved oncolytic viruses 
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Talimogene laherparepvec (T-VEC) also work as a useful tool in some clinical situations. 
The side effects of immunotherapy are like fever, achy muscles and joints, fatigue, and 
nausea. More serious side effects may occur when immune system goes into overdrive 
and starts to attack healthy tissues. What’s more, it also limited by its variable in response 
and slower onset of action in the clinical use [14,15] . As for targeted therapy, a small 
portion of melanomas have changes in the C-KIT gene that help them grow. Imatinib 
(Gleevec) and nilotinib (Tasigna) are targeted drugs that can affect cells with changes in 
C-KIT. The most frequent mutation in melanoma is BRAF protein and targeting MAPK 
pathway was found to benefit patients with BRAFV600E mutation [16,17]. The FDA 
approved targeted drugs that targeting BRAFV600E mutation in MAPK pathway were 
shown in table 1. Even though targeted therapy provides initial tumor regression, it only 
offers less than one-year disease control due to the resistance problem [18-20]. Cross 
resistance to MEK inhibitor was also found in cell lines that acquired BRAF resistance as 
well as enhanced the toxicity in the combination with BRAF inhibitor, thus limited the 
long-term survival of patients who harbors BRAF mutations [21-24]. The combination of 
targeted therapies with immunotherapy has also been explored, nevertheless, the frontline 
therapy for BRAF-mutant metastatic melanoma is still remaining to be decided due to 









Table 1. FDA approved drugs for targeting MAPK pathway of BRAFV600E mutated 











Product Active Ingredient Approval Date Mechanism(s) 
Zelboraf Vemurafenib August, 2011 BRAFi 
Mekinist Trametinib May, 2013 MEKi 
Tafinlar Dabrafenib May, 2013 BRAFi 
Mekinist + Tafinlar Trametinib + Dabrafenib January, 2014 MEKi +BRAFi 
Cotellic Cobimetinib November, 2015 MEKi 
Tafinlar + Mekinist Dabrafenib + Trametinib April, 2018 MEKi + BRAFi 
Mektovi + Braftovi Binimetinib + Encorafenib June, 2018 MEKi + BRAFi 
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1.3  Tumor stroma in melanoma  
Accumulating evidence has shown tumor stromal components play a major role in tumor 
microenvironment that affect melanoma tumorigenesis, progression and metastasis [28,29]. 
The tumor stroma mainly composes of extracellular matrix (ECM), immune 
cells, fibroblasts and signaling molecules. The homeostasis of normal skin melanocytic is 
dynamically regulated between the melanocytes and their microenvironment, such as 
keratinocytes, fibroblasts and the extracellular matrix [30]. However, during the 
development of melanoma from melanocyte, the interaction between neoplastic cells and 
surrounding stroma is deregulated. Fibroblasts exert a vital function in terms of 
regulating the homeostasis of ECM since it can secret proteolytic enzymes that can 
degrade ECM such as collagenase and matrix metalloproteases (MMPs), as well as 
collagens and other fibrous macromolecules [31].  Moreover, fibroblasts were involved in 
the crosstalk between cancer cells and cancer-associated fibroblasts (CAFs), which are 
the most crucial component in the tumor stroma that associated with tumorigenesis and 
immune system modulation in a context-dependent manner. The secreted growth factors 
from tumor cells can initiate the transition of normal fibroblasts to CAFs and CAFs will 
in turn secret more growth factors like transforming growth factor-β (TGF-β), fibroblast 
growth factor (FGF) and hepatocyte growth factor (HGF) and further promote migration 
and invasion of tumor cells [30,32]. CAFs are a prominent contributor in the desmoplastic 
tumor stroma and remodel ECM stiffness by crosslinking with collagen network and 
secreting cytokines to tumor stroma [32,33]. As a result, the stiffness of ECM will promote 
cell proliferation, increase adherence junction’s motility and activate epithelial-
mesenchymal transition [34,35]. Furthermore, this dense-than-normal niche isolate tumor 
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cells from the vessels can severely impedes nanomedicine interstitial transport [36]. 
Therefore, effective cancer therapies could be targeting tumor stroma besides tumor cells, 






















1.4  Liposomes 
 The liposomes have been widely studied as nano-vehicle in targeted delivery of 
chemotherapeutics for cancer treatment and were the first nano-scaled delivery system 
that translated into clinical use in 1995 [37,38]. Liposomes are lipid-based bilayer vesicles 
that consist of an aqueous core and can form spontaneously when phospholipids are 
dispersed in water. This formation is mainly related with hydrophilic and hydrophobic 
interactions between lipid-lipid and lipid-water molecules, then the lipid molecules will 
be arranged after the input of energy like sonication and homogenization to achieve a 
thermodynamic equilibrium and to curve them since the symmetric membranes prefer to 
be flat (spontaneous curvature Co=0) [39]. This particular structure allows the 
incorporation of hydrophobic molecules into the bilayer and hydrophilic molecules in the 
aqueous core. Among the distinct nanoparticulate systems that are investigated to date, 
liposomal carriers have proven to be advantageous over other types dosage forms due to 
the function of active and passive targeting that minimize off-target side 
effects, biocompatibility, enhanced bioavailability, solubility, biodistribution and 
systemic circulation of antineoplastic agents, which enhance the therapeutic index 
especially for those multifunctional liposomes with various combination mechanisms 
[38,40-42]. Because of the unique structure and the phospholipid being a safe and 
biocompatible excipient, substantiates to be superior when compared to nonionic 
surfactants and polymers for intravenous delivery.  
The mechanism of liposomes for passive tumor accumulation is known as  permeability 
and retention (EPR) effect. This phenomenon is due to the abnormal vasculature that the 
particle size in the range of 20–200 nm tends to to extravasate into the interstitial space. 
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The particle size out of the range of EPR effect will be either cleared by the kidney or too 
large to penetrate into the leaky vasculature of tumor tissue [43]. The enhanced retention 
of nanoparticle is due to the lack of lymphatic drainage. However, the EPR effect is more 
complicated than previously thought as the extent of EPR effect depends on many factors 
such as heterogeneity of pathophysiological phenomenon and tumor microenvironment 
[44].  
Further, surface PEGylation of nanoparticle is preferred to bypass the reticuloendothelial 
system and proteolytic enzymatic degradation [45]. Active targeting liposomes can 
specific target overexpressed receptor or molecules of the cancer cells by attaching 
certain moieties on the surface of liposomes, which includes nucleic acids, small 
molecules, peptides, proteins, carbohydrates, or monoclonal antibodies [46,47].  
Nevertheless, pharmaceutical manufacturing, government regulations and intellectual 
property limited the translation to the clinical application [48,49]. Thus, communication 











1.5  Literature review 
Significant improvement in clinical outcomes with the introduction of targeted therapies 
based therapeutic regimen has remarkably changed the survival statistics of BRAF-
mutated metastatic melanoma in recent years, and MEKi was combined with BRAFi has 
been shown to improve clinical benefit including progression-free survival, overall 
survival and response rate [21,22,50]. However, off target toxicities lead to dose 
interruption, restrict the dose escalation and warrant reduction in the dose of BRAFi and 
MEKi especially trametinib (TMB). Dose dependents side effects associated with 
trametinib are: Cardiac, an absolute decrease of >10% in left ventricular ejection fraction 
(LVEF), ocular and interstitial lung disease (ILD), rash, hypertension, fatigue, peripheral 
edema, diarrhea and acneiform dermatitis etc [51,52]. Central serous retinopathy (CSR) 
and hypertension require dose modification. Management of LVEF requires withhold 
TMB doses for four months or in severe case permanent discontinuation of TMB [52]. 
The adverse events (AEs) observed in the patients treated with the combination of BRAFi 
and MEKi are not as common as those treated with chemotherapy and the percentage of 
patients with AEs is higher than with vemurafenib monotherapy due to the toxicity of 
MEKi, thus the dose modifications or interruptions are usually required to optimize the 
use of the treatment base on the effective side-effect management [23]. Therefore, drug 
delivery to the desired site is preferential for metastatic melanoma tumor cell targeting 
which prevents unwanted cell destruction. 
BRAFi Vemurafenib has been approved by FDA in 2011 for first-line treatment of 
metastatic melanoma in 2011 due to its promising clinical efficacy [53]. Unfortunately, 
patients developed vemurafenib-resistance and eventually relapsed over an average of 6 
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to 8 months [54]. Additionally, cross-resistance of combined BRAF/MEK Inhibition was 
found in acquired BRAFi resistance [18,20,55]. Various resistant mechanisms have been 
studied for acquired resistance to BRAFi such as reactivation of the MAPK signaling 
pathway or PI3K-AKT pathway, upregulation of tyrosine kinase receptor and interactions 
with the tumor microenvironment [56]. Possible alternative combination therapies and 
clinical investigations to overcome BRAFi-caused resistance in melanomas with 
BRAFV600E mutation has been extensively discussed and studied [57,58].  
Emerging data has suggested that the pathogenesis of melanoma is due to the aberrant 
activity of epigenetic regulation of the transcriptional process through the modification of 
DNA and chromatin, which affected melanoma promotion, metastasis and drug resistance 
[59,60]. Overexpressed c-MYC was reported to drive melanoma metastasis and major 
resistance pathways were found to converge to activate c-MYC [61,62]. c-MYC is a major 
transcriptional factor directly regulated by BRD4 and controls almost all cellular 
processes. However, the lacking of specific active site makes the direct therapeutic 
targeting difficult [63]. Indirect targeting to c-Myc by BET bromodomain inhibition was 
proved as therapeutic strategy in recent years [64-66]. It was also reported that BRD4 is 
significantly upregulated in primary and metastatic melanoma tissues compared to 
melanocytes and thus to be considered as a new target for therapeutic strategy [62]. BRD4 
is one of the family members of bromodomain and extraterminal domain (BET) proteins, 
which also contains BRD2, BRD3 and BRDT. BRD4 is an epigenetic reader that 
regulates gene transcription and cell cycle through recruiting transcriptional regulatory 
complexes to chromatin [67]. BRD4 contains two N-terminal bromodomains (BD1, BD2) 
that bind to acetylated lysine residues of histone tails or other nuclear proteins and 
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influence gene transcription both at initiation and elongation step, as well as affect the 
expression of oncogenes and anti-apoptotic proteins like Bcl-2 and Bcl-xl [59,68]. 
Additionally, manipulation BET proteins in melanoma could offset resistance problems 
and enhanced BRAF/MEK inhibitors efficacy in melanoma [69-71].  
PROteolysis-TArgeting Chimeric (PROTAC) technology, using “a kiss of death” to 
destroy ‘undruggable’ proteins has been discovered in 2001 and was considered as next-
generation tool for chromatin regulation [72,73]. The first cereblon-based BRD4 PROTAC 
molecule ARV-825 was developed by researchers from Yale University and Arvinas, 
which selectively degrade BRD4 protein by hijacking the E3 ubiquitin ligase cereblon 
instead of mere inhibiting it, resulting in quick and prolonged degradation of BRD4 
compared to traditional small molecule inhibitors [74]. Moreover, ARV-825 was proved 
to be a novel therapeutic molecule for the treatment of vemurafenib-resistant melanoma 
[75]. 
It was reported that melanoma cells can stimulate the recruitment of fibroblasts and 
activate them, which contributed to melanoma growth as well as drug resistance [76]. 
Fibroblasts is one of the most predominant cell types that deposit extracellular matrix 
(ECM), which is associated with all stages of cancer development [30,31]. It was reported 
that stromal fibroblasts can be activated into cancer-associated fibroblasts (CAFs) since 
the secretion of growth factors such as transforming growth factor-β (TGF-β) from 
cancer cells, in turns, CAFs can further stimulate tumorigenesis, migration, invasion and 
metastasis of cancer cell by secreting more growth factors like TGF-β to the stromal 
ECM [32]. This crosstalk between cancer cells and CAFs remodel the stromal 
extracellular matrix (ECM) and contribute to the cancer progression. TGF-β is one of the 
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major cytokines that derived from CAFs and was found to increases survival of human 
melanoma through stroma remodeling [33]. BRAF inhibitor vemurafenib treated 
melanoma cells was found to led TGF-β release, which increased the deposition of 
fibronectin, type I collagen and α-smooth muscle actin [34,35]. Type I Collagen and 
hyaluronic acid rich dense extracellular matrix of solid tumor serves as a tortuous, 



















2  Purpose of Study 
The treatment for BRAF-mutant metastatic melanoma has been widely explored aiming 
to improve the therapeutic benefit, however, the sever toxicity and resistance problems 
are mainly limited the effectiveness of the therapeutics. Therefore, the purpose of the 
present research was aiming to address the current problems for BRAF-mutant metastatic 
melanoma in two perspectives as following: 
 
I) There have been no studies demonstrating EphA2 receptor-targeted nanoparticles with 
anticancer agents for metastatic melanoma. The first part of the thesis project focus on 
developing active-targeting nanoliposomes to reduce toxicity of the targeted therapy 
(TMB) for the treatment of BRAFV600E-mutated melanoma.  
Specific Objectives include: 
(1) To develop and characterize YSA-anchored trametinib loaded PEGylated liposomes 
(YTPL). 
(2) To evaluate anti-melanoma efficacy of YTPL in BRAFV600E-mutated parent cells 
(lines A375 and SK-MEL-28) and vemurafenib-resistant cells lines (A375R and SK-
MEL-28R) in melanoma. 
 
II) The second part of the thesis aim at investigating the effect of BRD4 proteolysis 
targeting chimera (PROTAC) molecule (ARV-825) and anti-fibrotic agent (Nintedanib) 
combination and developing a nanoliposomes to resolve the vemurafenib-resistance 




Specific Objectives include: 
(1) To evaluate the cytotoxic interaction of BRD4 PROTAC (ARV-825) and anti-fibrotic 
agent (Nintedanib) in BRAFV600E-mutated vemurafenib-resistant melanoma cells. 
(2) To develop and characterize dual ARV and Ninedanib-loaded PEGylated 
nanoliposomes (ARNIPL). 
(3) To evaluate anticancer efficacy of ARNIPL in BRAFi resistant human melanoma in 



















3  EphA2-Receptor Targeted PEGylated Nanoliposomes for 
the Treatment of BRAFV600E Mutated Parental and Resistant 
Melanoma  
3.1  Drug (Trametinib) 
Trametinib (Mekinist™) is a small molecule that approved as single-agent oral treatment 
for unresectable or metastatic melanoma in adult patients with BRAFV600E/K mutations by 
FDA in May 2013, each 1mg tablet contains 1.127 mg trametinib dimethyl sulfoxide 
equivalent to 1 mg of trametinib non-solvated parent with the recommended dose 2 mg 
once daily taken at least 1 hour before or at least 2 hours after a meal [77]. Trametinib is a 
mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitor that can selectively 
bind to unphosphorylated MEK1 and MEK2 with high affinity and allosterically inhibits 
their kinase activity, thus suppress the growth factor-mediated cell signaling pathway that 
involve in cell proliferation, survival and differentiation [77-79]. The properties of 
Trametinib was shown in Table 2. Trametinib was combined with BRAF inhibitor 
dabrafenib in order to delay the resistance to BRAF inhibition [80]. FDA approved the 
combination of trametinib with dabrafenib on January,2014 for the treatment of 
BRAFV600E/K mutant metastatic melanoma and on May, 2018 as an adjuvant treatment for 
BRAFV600E mutated, stage III melanoma after surgical resection based on the results of 





Table 2. Trametinib drug profile 
Name Trametinib 
Chemical Name N-[3-[3-cyclopropyl-5-(2-fluoro-4-iodoanilino)-6,8-dimethyl-2,4,7-trioxopyrido[4,3-d]pyrimidin-1-yl]phenyl]acetamide 
Molecular formula C26H23FIN5O4 




CAS No. 871700-17-3 
Melting point 299℃-301℃ 
LogP 1.965 
Solubility DMSO 32 mg/mL, Water <1.2mg/mL, Ethanol <1.2mg/mL 




3.2  Erythropoietin-producing hepatocellular (EphA2) receptor   
EphA2 is a protein tyrosine kinase receptor that belongs to Eph family and it bind to 
ephrin-A ligands through glycosphosphatidylinositol linkage [83]. Normally, EphA2 
expressed in the epithelial and endothelial cells while it has been found to be as a 
promoter of melanoma tumorigenicity [84]. Recent studies demonstrated the pivotal role 
of overexpressed EphA2 receptors in aggressiveness, metastatic potential, and 
vasculogenic mimicry in malignant melanoma [84,85]. EphA2 is also considered a growth 
receptor for malignant melanoma [86]. Melanoma tumor samples from patients taken 
prior to or after treatment with BRAFi and MEKi showed very high expression of EphA2 
in both BRAFV600E and BRAFWT melanomas. Compared to the EphA2 expression in 
malignant melanoma, normal tissues have low EphA2 expression, and therefore using 
YSA peptide-anchored nanocarriers for drug delivery may reduce off target side effects 
by reducing exposure of cytotoxic drugs to normal cells [87]. Moreover, upregulation of 
the EphA2 receptor was observed in BRAFi-resistant cell lines (such as A375 and SK-
MEL-28) [88]. Thus, the cell surface EphA2 receptor could be a potential target not only 
for treatment but also for delivering a high payload of anti-melanoma drugs. Wu et al. 
demonstrated that YSA-conjugated paclitaxel was more effective in murine melanoma 
compared to paclitaxel alone [89]. Moreover, YSA-anchored nanocarriers can carry a 






3.3  Materials 
Trametinib was purchased from LC Laboratories (Woburn, MA, USA); 1,2-Dioleoyl-sn-
glycero-3phosphocholine (DOPC) was purchased from Cordenpharma (Liestal, 
Switzerland); PE 18:0/18:0-PEG2000 was obtained from Lipoid (Ludwigshafen, 
Germany); cholesterol, chloroform, and a Sephadex G50 column were purchased from 
Sigma-Aldrich (St. Louis, MO, USA); 6-histidine tagged PEGylated (PEG) YSA (6His-
PEG-YSA) was obtained from GenScript Corporation (Piscataway, NJ, USA); (1,2-
dioleoyl-sn-glycero-3-[N-(5-amino-1-carboxypentyl)-iminodiacetic acid] succinyl (nickel 
salt) (DOGS-NTA-Ni)) was obtained from Avanti (Alabaster, AL, USA); Fetal Bovine 
Serum (FBS) was procured from Atlanta Biologics (Oakwood, GA, USA); Dulbecco’s 
modified Eagle’s medium (DMEM) and the BCA protein estimation kit were purchased 
from ThermoFisher Scientific Inc. (Waltham, MA, USA); Penicillin–Streptomycin–
Amphotericin B (PSA) was purchased from MP Biomedicals, LLC (Solon, OH, USA); 
and ALW-II-41-27 was obtained from Cayman Chemical (Ann Arbor, MI, USA). Other 
chemicals and solvents were of analytical grade. Melanoma cell lines (A375 and SK-










3.4  Methods 
3.4.1  Analytical Method 
Chromatographic separation of TMB was achieved using Waters e2695 separation 
module, a 2998 PDA detector instrument equipped with a Hypersil ODS C18 column 
(250mm´4.6mm,5µm). Acetonitrile: phosphate buffer pH 3.5 (70:30) was used as the 
mobile phase with a flow rate of 1 mL/min and an injection volume of 10 µL. The 
column temperature was kept at 25 °C and the output signal was detected using Empower 
3 software. The retention time of TMB was found to be 4.7 min, detected at 248 nm. All 
















3.4.2  Cell Culture 
Vemurafenib-resistant cell lines (A375R and SK-MEL-28R) were generated by adding 
0.2 µM of vemurafenib to the media of A375 and SK-MEL-28 for 2 months. The 
vemurafenib resistance was confirmed prior to studies. All cell lines were maintained in 




















3.4.3  Preparation of Liposomes 
Initially, liposomes were prepared by modified hydration methods. Briefly, TMB: 
DOGS-NTA-Ni: DOPC: cholesterol: DSPE-PEG 2000 in a 1:0.75:60:16.3:2.1 molar ratio 
was dissolved in chloroform. DOPC, cholesterol, DSPE-PEG, and TMB were dissolved 
in chloroform. For thin film hydration, the solution was taken in a round bottom flask 
under vacuum to form a film, followed by hydration with water at 55 °C and 
ultrasonication (30% amplitude) for 2 min. For the modified hydration method, the same 
chloroform solution was added dropwise to parenteral-grade mannitol (200 µm) with 
constant stirring at 45 °C and left overnight for evaporation of chloroform. Dispersion of 
this resultant powder was prepared in water at 55 °C and was sonicated (30% amplitude) 
for 2 min. For the investigation of the effect of mannitol on stability, mannitol was 
separated from liposomes using a Sephadex G50 column. For preparation of YTPL, first 
DOGS-NTA-Ni-loaded liposomes were prepared using the same composition and 
method described above. Liposomes were incubated with different concentrations of 









3.4.4  Characterization of liposomes 
The average size, size distribution by intensity, zeta potential, and polydispersity index 
were measured using a dynamic light scattering (DLS) particle size analyzer (Malvern 
Zetasizer Nano ZS, Royston, UK). Samples were analyzed using disposable cuvettes at 
25 °C with a scattering angle of 173°. The effect of YSA concentration on particle size 
and zeta potential was evaluated. All the experiments were carried out in triplicates. 
Entrapment efficiency was estimated using ultrafiltration by Amicon ultra centrifugal 
filters (50K). The concentration of TMB was analyzed by HPLC. The encapsulation 
efficiency of TMB was expressed as the percent of drug encapsulated and calculated 
using the following formula: 













3.4.5  Stability Study 
TPL at different drug loading values (1%, 2.5%, and 4%) was prepared for the stability 
study. Total drug content was measured at time zero. Samples were withdrawn at 





















3.4.6  Freeze Drying of Liposomes 
TPL with 1% drug loading was used to investigate the effect of concentration of 
cryoprotectant (2.5%, 5%, 7.5%, 10% trehalose) on freeze drying. TPL was prepared 
using the method described above (unfiltered TPL). Further, unfiltered TPL was passed 
through a Sephadex G50 gel column to separate mannitol. Mannitol-free TPL was 
referred to as filtered TPL. Briefly, 1-mL aliquots of the liposomal dispersions were filled 
into colorless glass vials and then stored at -80 °C overnight, followed by lyophilization 
(Labconco FreeZone 2.5, -53 °C at 12 Pa) overnight in order to achieve a preservable 
white powder. The same protocol was used for freeze drying of YTPL. Lyophilized 
liposomes were reconstituted with water. Particle size, zeta potential, and YSA binding 
efficiency were analyzed before and after freeze drying of YTPL. For YSA binding 
efficiency, 400 μL of YTPL were filled into Amicon Ultra centrifugal filters (30 kDa) 
(Millipore, Ireland). Free YSA was separated by centrifuging the samples at 10,000 rpm 
for 10 min. Concentration of free YSA (before and after freeze drying) was analyzed 
using a BCA protein estimation kit (Thermoscientific, Waltham, MA, USA). Briefly, 400 
μL of YSA coated liposomes was filled into Amicon Ultra centrifugal filters (30 kDa) 
(Millipore, Ireland) and free YSA was separated by centrifuging the samples at 10,000 
rpm for 10 min. Concentration of free YSA (before and after freeze drying) was analyzed 






3.4.7  Differential Scanning Calorimetry (DSC) Thermograms of TMB 
and TPL 
Analysis of TMB and TPL was carried out to evaluate the physical state of TMB in 
liposomes using a Q200 modulated DSC instrument (TA Instruments, New Castle, DE, 
USA). The liposomal formulation was dried, and the semi-solid paste was weighed in an 
aluminum pan and hermetically sealed. The samples were equilibrated at 25 °C for 5 min 
and were heated at the rate of 10 °C/min from 40 °C to 350 °C. A hermetically sealed 
empty aluminum pan was used as a reference. TA Instruments Universal Analysis 2000 
















3.4.8  In Vitro Release Study 
Drug release from TPL was carried out using the dialysis bag method. Before use, 
dialysis bags (Spectra/Por® 7) were soaked before use in Milli-Q water at room 
temperature overnight to remove the preservative, followed by rinsing thoroughly in 
Milli-Q water. Drug release of TMB from TPL was carried out in a dialysis sac with 200 
mL of phosphate buffer saline (pH 7.4) containing 0.5% Kolliphor EL at 37 °C with 
constant stirring. The samples were withdrawn from the release medium at different time 

















3.4.9  In Vitro Hemolysis Study 
Rat red blood cells (RBCs) were separated from plasma by centrifugation at 2000 rpm for 
5 min. The cell pellet was re-dispersed into an appropriate volume of PBS to achieve the 
same hematocrit. Then, 1 mg/mL TMB of TPL was added to the RBC dispersion to 
achieve 100, 50, 10, and 2 µg/mL TMB concentrations. After 30 min of incubation at 
37 °C, samples were centrifuged at 2000 rpm for 10 min. Supernatants were diluted with 
PBS and analyzed. A UV spectrophotometer was used to evaluate the hemoglobin release 
at 550 nm. PBS was used as the negative control, and sodium lauryl sulfate solution was 
used as the positive control (100% hemoglobin release). Percentage hemolysis was 
calculated by following formula: 
% hemolysis = (absorbance of test sample – absorbance of negative control)/ (absorbance 













3.4.10  Plasma-to-Blood Ratio 
TPL was added to blood to prepare TMB at a concentration of 50 µg/mL (n = 6). 
Samples were incubated at 37 °C for 30 min and then samples were centrifuged. Plasma 
was separated from centrifuged samples. Sodium lauryl sulfate was added to half the 
samples for complete hemolysis. The TMB concentration in hemolyzed blood and plasma 
was analyzed by HPLC. The plasma-to blood ratio was calculated by the equation given 
below: 

















3.4.11  Cellular Uptake of Liposomes 
Cells were plated in a 96-well plate at a density of 10,000 cells/well and incubated at 
37 °C and 5% CO2 for 48 h before treatment. Coumarin-6 loaded PEGylated liposomes 
(TPL) and YSA-anchored coumarin-6-loaded PEGylated liposomes (YTPL) were 
incubated with cells for 1 h. Afterwards, cells were washed with HBSS and fixed with 
3.7% formalin. Uptake of TPL and YTPL in different cell lines was observed for same 


















3.4.12  In Vitro Cytotoxicity Test 
SK-MEL-28R cell lines using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) assay. ALW-II-41-27 (an EphA2 receptor ATP-competitive inhibitor), 
vemurafenib, and vemurafenib with 0.1 µM ALW-II-41-27 were tested in both SK-MEL-
28 and SK-MEL-28R. Cells were seeded in 96-well plates at a density of 5000 cells/well 
and allowed to grow for 24 h before treatments. TMB and TPL were diluted in cell 
culture medium at different concentrations. After 48 h treatment, cell viability was 
determined by the MTT assay. Briefly, MTT dye was dissolved at a final concentration of 
5 mg/mL in PBS. Cells were incubated with 20 µL of 5 mg/mL MTT solution in each 
well for 3 h at 37 °C, 5% CO2. Then the medium was removed from wells and MTT-
formazan crystals were dissolved by the addition of 100 µL of dimethyl sulfoxide 
(DMSO) to each well. The quantity of MTT-formazan was determined by 570 nm 













3.4.13  Western Blot Assay 
Whole cell protein lysates were obtained from A375, SK-MEL-28, A375R, and SK-
MEL-28R cell lines. Briefly, cells were scraped in modified RIPA buffer (50 mM Tris, 
150 mM NaCl, 1% v/v NP-40, 0.5% w/v deoxycholate, 0.1% w/v SDS, 10% v/v glycerol, 
10 mM NaF, 0.4 mM EDTA, pH 8.0) with protease inhibitors. The lysates were cleared 
by centrifugation at 10,000 g for 10 min and then reduced with Laemmli buffer 
containing β-mercaptoethanol, separated on 4–15% MiniProtean TGX gels (Bio-Rad, 
Deesid, UK), transferred to a PVDF membrane, and probed with primary antibodies from 
Cell Signaling Technology for EphA2 (6997) and β-actin (8457) for chemiluminescence 
















3.4  Results and Discussion 















3.4.2  Preparation of TMB-Loaded PEGylated Liposomes 
Since there are no previous reports on formulation development of TMB, we explored 
four different methods for preparation of TPL, which were compared and optimized 
based on formulation feasibility and physical stability. The results of TPL prepared using 
different methods are given in Table 3. Due to the poor solubility of TMB in ethanol and 
ether, the ethanol injection method and ether injection method were not used for the 
preparation of TMB liposomes. The thin film hydration method is a commonly used 
method for the preparation of liposomes. However, around 50% of the drug precipitated 
from TPL in 2 h. Moreover, entrapment efficiency was only 51.6%. Because of the poor 
entrapment and physical stability of TPL prepared using a thin film hydration method, we 
adopted a modified hydration method, which showed 96.2% entrapment of TMB and 
better physical stability (absence of TMB precipitation within 24 h) compared to the thin 
film hydration method. Thus, a modified hydration method was used for further 
















Method Solubility of TMB Entrapment Efficiency of TPL (1% w/w TMB loading) 
Thin film hydration Soluble 51.6% 
Modified hydration Soluble 96.2% 
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3.4.3  Particle Size and Zeta Potential 
Particle size and zeta potential of nanoparticles play an important role, especially for 
parenteral administration. Different concentrations of 6His-PEG-YSA peptides were used 
to optimize particle size and zeta potential. The succinyl group of DOGS-NTA-Ni 
contributes to negative zeta potential of the liposomes. The hydrodynamic diameter of 
TPL prepared using a modified hydration method was found to be 109.45 ± 9.40 nm with 
a zeta potential of -35.55 ± 9.60 mV. The zeta potential of DOGS-NTA-Ni-loaded 
liposomes was lower than TPL. For YTPL, particle size was found to be similar at all the 
DOGS-NTA-Ni:YSA ratios (Figure 3). A slight decline in particle size from 109.45 nm 
to 89.75 nm was observed after incubation with YSA. An increase in the zeta potential of 
liposomes was observed in a concentration-dependent manner due to the surface 
complexation of YSA (Figure 1b). Since electropositive transition metals Ni showed high 
affinity to bond with side chain of Hstidine, imidazole. Therefore, Nickel-chelating lipids 
DOGS-NTA-Ni can bind with hexahistidine chain of YSA peptide, and allow one simple 
step of YSA to attach on the surface of the liposomes. Due to the complexation between 
the YSA target ligand and DOGS-NTA-Ni, the zeta potential changed from negative to 
positive in a YSA concentration-dependent manner. The zeta potential significantly 
increased from -28.10 mV to -0.92 mV upon addition of 1:1.25MDOGS-NTA-Ni: YSA. 
Thereafter, there was only a slight increase in zeta potential at higher ratios (e.g., 1:2.5 
and 1:5), suggesting that YTPL was saturated with YSA. Thus, a 1:2.5 molar ratio of 






Figure 3. Effect of YSA (YSAYPDSVPMMS) concentration on (a) particle size and (b) 
zeta potential. Data are given as mean ± SD (n = 3). No significant change in particle size 

















3.4.4  Stability of Liposomes 
The precipitation of a hydrophobic drug from liposomes is another issue with respect to 
long term stability. In order to evaluate the physical stability, TPL with different drug 
loading values (1%, 2.5% and 4%) at a 0.5 mg/mL TMB concentration were prepared. As 
expected, we observed that lower the drug loading, the lower the percentage of TMB 
precipitation (Figure 4). Moreover, the precipitation increased with time. For TPL with 
4% drug loading, more than 25% of the drug precipitated within half an hour, while at 
2.5% drug loading of TPL, the precipitation was slower compared to 4%. However, more 
than 14% of the drug precipitated in 1 h. An increase in percentage precipitation with 
time suggested that TPL in liquid form may not be stable for long periods. Thus, 
considering the poor physical stability of TPL in liquid form, freeze drying was carried 
out. TPL with 1% loading was considered for freeze drying. Moreover, we investigated 
the effect of storage conditions (room temperature and 4 °C) on liposome stability. For 
4% and 2.5% drug loading, precipitation was significantly affected by storage conditions. 
For 1% drug loading, precipitation was less than 5% at room temperature and 4 °C in 24 
h (Data not shown). Nevertheless, we observed a very slow but steady increase in drug 
precipitation from liposomal formulation over the time period. Thus, it was essential to 







Figure 4. Stability study of TPL.  % precipitation of TPL with varying drug loading 
values. Precipitation significantly increased with higher drug loading compared to 1% 














3.4.5  Freeze Drying of Liposomes 
For liposomes with poor physicochemical stability, spray drying or freeze drying are used 
to address the stability problem. Freeze drying, also known as lyophilization, is the most 
commonly used method to dry liposomal dispersions. This technique is widely used for 
pharmaceuticals to improve their long-term storage stability [91]. AmBisome® and 
Visudyne® are available as lyophilized liposomal powders [92]. Trehalose is one of the 
most widely used cryoprotectant and it usually exerts the best protective effect among the 
disaccharides. Trehalose-based products such as Avastin®, and Lucentis® are 
commercially available. Trehalose has an ability to reduce hygroscopicity so that 
hydrogen bonds can form easily, has low chemical reactivity, and has a high glass 
transition temperature (Tg) [93]. Mannitol was used as a carrier for the liposomes and it is 
generally not advised for stabilizing liposomes because it may separate from a frozen 
solution or crystallize within the lyophilized cakes [94,95]. 
 
Freeze drying was carried out to covert TPL into solid powder for reconstitution. Since 
TPL was prepared using a modified hydration method that contains mannitol, we 
evaluated the effect of mannitol on TPL stability. Unfiltered TPL are liposomes without 
the separation of mannitol. Filtered TPL was prepared by separating mannitol using a 
G50-Sephadex column while the unfiltered TPL was the liposome which had not 
undergone filtering of the mannitol. Particle size and zeta potential of unfiltered and 
filtered TPL before and after freeze drying with various concentrations of trehalose are 
depicted in Figure 5. We observed that concentration of trehalose plays a significant role 
in the particle size of reconstituted TPL. Batches with 5% and 7.5% of trehalose 
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exhibited a paste-like appearance with poor flow properties and took a longer time for 
reconstitution. TPL with 10% trehalose gave free flow powder and could be reconstituted 
within 5 min with the original particle size and zeta potential. For TPL with 2.5% 
trehalose, reconstitution could not be achieved. Therefore, 10% trehalose was used for 
freeze drying of optimized YTPL. Freeze-dried liposome contains 2.83 µg TMB/mg of 
powder. No significant change of zeta potential was observed, as shown in Table 4. 
Particle size was increased but was still within 200 nm. Moreover, the encapsulation 
efficiency of YTPL remains the same (>96%) as before freeze drying. No significant 
different of YSA binding percentage was observed before and after freeze drying (more 



















Figure 5. Effect of trehalose concentration of TPL on (a) Zeta potential (b) Particle size 
after freeze drying. Trehalose concentration has a major effect on particle size and a 
minor effect on zeta potential. Data are given as mean ± SD (n = 3). 
 
 
Table 4. Particle size and zeta potential of YSA-anchored TMB-loaded nanoliposomes 








3.4.6   DSC Thermograms of TMB and TPL 
Differential scanning calorimetry (DSC) studies can be used for liposome quality control 
by thermal analysis to determine purity, polymorphic forms, and the melting point of the 
sample [96]. DSC endotherms of TMB and TPL were obtained as shown in Figure 6. 
TMB showed a sharp endothermic peak of pure TMB at 300 °C, which suggests that the 
pure TMB was in a crystalline form. As expected, liposomes did not show any melting 
endothermic peak. Therefore, the absence of a sharp endothermic peak at 300 °C in 
liposomes confirmed that TMB was not in a crystalline or precipitated state but was in a 

















Figure 6. Solid-state characterization of TPL. Differential scanning calorimetry (DSC) 
thermograms of TMB and TPL. Green peak showed a crystalline form of TMB; the 






3.4.7  Drug Release Study 
The release of liposomes is important to evaluate the quality of the formulation as well as 
to predict in vivo behaviour of a liposomal drug delivery system. In this study, TPL 
showed less than an 8% drug release in 24 h at sink conditions (Figure 7), which 
indicated that TPL did not leak or have burst release of TMB from the liposomes. We 
anticipate that TPL will follow a similar release behavior in vivo. TMB will be confined 
within the liposome and will not show any burst release in the blood. However, it showed 
promising activity in our in vitro studies, indicating that TMB will be released and act 
after internalization by cancer cells. We expect liposomes to accumulate at tumor site due 
to the EPR effect, and for complete release of TMB at the tumor site in vivo due to the 
active-target effect. Sink condition was maintained by adding a non-ionic surfactant 
















Figure 7. In vitro release study of TPL. No hemolysis was observed. Limited amount of 










3.4.8  In Vitro Hemolysis Study and Plasma to Blood Ratio 
Negligible hemolysis was observed even at 100 μg/mL of TMB used (Figure 8, Table 5). 
Further, very quick and complete redispersion of red blood cells (RBCs) implied that the 
surface characteristics of RBCs were not altered by TPL. The blood-to-plasma ratio 
determines the concentration of the drug in the general circulation and the concentration 
of the target drug in plasma, which provides an indication of drug the binding to 
erythrocytes. The result for blood-to-plasma ratios of TMB is around 1 which indicates 


















Figure 8. In vitro hemolysis study of TPL at various TMB concentrations. 
 
 











3.4.9  Uptake Study  
Coumarin-6 was selected as the fluorescent dye for labelling the liposomes. The intensity 
of this fluorescence dye can be correlated with the extent of liposome uptake. As shown 
in Figure 9, the intensity of green fluorescence was significantly higher in YTPL-treated 
cells compared to TPL-treated cells due to the targeting peptide. Moreover, A375 and 
SK-MEL-28 cell lines showed higher intracellular fluorescence intensity than A375R and 
SK-MEL-28R for YTPL due to the higher expression of EphA2 receptors, which 



















Figure 9. Uptake study of TPL and YTPL of BRAFV600E mutated parent and 
vemurafenib-resistant melanoma cell lines. High intensity of fluorescence was observed 
with targeted liposome treatment and resistant cell lines showed less uptake of liposomes. 








3.4.10  In Vitro Cytotoxicity Test  
In vitro cytotoxicity of TMB, TPL, and YTPL was evaluated in patent cell lines only. 
IC50 values of each of the formulations is given in Table 6. The IC50 values for TMB, 
TPL, and YTPL were similar at around 0.7 nM. Cell viability graphs of TMB, TPL, and 
YTPL in melanoma cell lines are given in Figure 10. The very low IC50 of the TMB 
liposome confirmed that TMB was released after internalization of TPL into cancer cells. 
Moreover, the IC50 values of TMB, TPL, and YSL are similar in A375 and SK-MEL-28, 
while in-vivo behavior may vary due to drug distribution and the microenvironment of 
the tumor.  
 
To further investigate whether the EphA2 receptor was correlated with vemurafenib-
resistance, ALW-II-41-27, an EphA2 ATP-competitive inhibitor, inhibited the growth of 
SK-MEL-28 and SK-MEL-28R in a concentration-dependent manner (Figure 11). The 
IC50 values of ALW-II-41-27 were 122.4 nM and 177.0 nM for SK-MEL-28 and SK-
MEL-28R, respectively. Co-treatment with ALW-II-41-27 did not alter the cytotoxicity 
of vemurafenib in parent or vemurafenib-resistant SK-MEL-28 cells. Vemurafenib 
diluted in 0.1 µM ALW-II-41-27 showed similar viability compared to single 
vemurafenib treatment, which indicates that the EphA2 inhibitor did not change the 
resistance sensitivity. Thus, EphA2 receptor inhibition is not co-related to cytotoxicity of 






Table 6. In vitro cytotoxicity of TMB, TPL, and YTPL in A375 and SK-MEL-28. 
 
 
Figure 10. Cytotoxicity assay in melanoma cell lines. % Cell viability of (a) A375 cells 
and (b) SKMEL-28 cells after treatment of TMB, (TMB loaded PEGylated Liposomes) 









Figure 11. Cytotoxicity assay in parent and vemurafenib-resistant melanoma cell lines 
(a) % Cell growth inhibition of SK-MEL-28 and SK-MEL-28R after ALW-II-41-27 
treatment (b) % Cell viability of SK-MEL-28 and SK-MEL-28R after vemurafenib 
treatment with and without ALW-II-41-27. Vemurafenib was incubated with 0.1 µM 
ALW-II-41-27. Results showed no difference in viability compared to a single 
vemurafenib treatment alone. 
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3.4.11  Western Analysis  
The protein expression of EphA2 was significantly lower in the whole cell lysates from 
A375R and Sk-MEL-28R melanoma cell lines compared to A375 and Sk-MEL-28 
(Figure 12). The results further confirm that the expression of EphA2 receptor is higher 
in BRAFV600E-mutated melanoma parent cell lines compared to the resistant cell lines. 
 
 
Figure 12. Western blot analysis of EphA2 receptor proteins in A375 and A375R cell 
lines. Higher EphA2 receptor expression was observed in BRAFV600E-mutated cell lines 









4  Development of Dual ARV-825 and Nintedanib - Loaded 
Nano-liposome for synergistic efficacy in Vemurafenib-
resistant Melanoma 
4.1  Drug 
4.1.1  ARV-825 
ARV-825 is a the first cereblon-based BRD4 PROTAC molecule that developed by 
researchers from Yale University and Arvinas [74]. It can specifically target BRD4 
protein and showed faster and prolonged degradation of BRD4 protein compared to other 
BRD4 inhibitors. It is a hetero-bifunctional molecule composed of a ligand binding to the 
target protein BRD4 joined via an ethoxy spacer linker. Thienodiazepine part of ARV-
825 recruits BRD4 directly to the E3 ubiquitin ligase cereblon, which binds to the 
phthalimide part of ARV-825. It has been previously revealed that ARV-825 exhibited 
promising efficacy for the treatment of vemurafenib-resistant melanoma, however, it was 
found as a substrate of CYP3A4 with short half-life [75]. According to Lipinski rule of 
five, the violations for ARV are two, which are number of hydrogen bond acceptor 
(should be less than 10 while ARV has 17) and molecular weight (should be less than 500 
g/mole while ARV is 941 g/mole) [97]. Moreover, the polar surface area of ARV is 
233 °A2, whereas the polar surface area should be < 140 °A2 for good oral absorption. 
Therefore, oral administration route may not be suitable for the delivery of ARV-825. 
Additionally, ARV is an extremely poor water-soluble molecule, which pose a significant 
challenge in development of translational parenteral formulation. The profile of ARV-
825 was outlined in Table 7. 
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Molecular weight 941.40 g/mol 
Structure 
 
CAS No. 1818885-28-7 









4.1.2  Ninetidanib  
Nintedanib is a Food and Drug Administration (FDA) approved anti-fibrotic agent for the 
treatment of idiopathic pulmonary fibrosis in 2014 and along with other drugs like 
docetaxel for the treatment of non-small cell lung cancer. It was sold under the brand 
names Ofev and Vargatef that developed by Boehringer Ingelheim. Nintedanib was 
reported to inhibit vascular endothelial growth factor receptor (VEGFR) 1–3, platelet-
derived growth factor receptor (PDGFR)-α and -β, and fibroblast growth factor receptor 
(FGFR) 1–3 [99]. Furthermore, nintedanib could inhibit ECM proteins like fibronectin, 
type I collagen and transforming growth factor (TGF)-β1-induced myofibroblast 
transdifferentiation, all of which contribute to the reduction of dense network in the 
tumor extracellular matrix [100,101]. Nintedanib is reported as a substrate of the 
transporter P-glycoprotein, which transports the absorbed substance back into the gut's 
lumen [102]. Nintedanib was selected here as an anti-fibrotic agent and the uptake of 
nanotherapeutics would be increased due to the tumor stroma devastation by inhibiting 









Table 8. Nintedanib drug profile 
Name Nintedanib 
Chemical Name 4-(p-chlorophenyl)-4-hydroxy-N, N-dimethyl- a, a-diphenyl-1-piperidinebutyramide monohydrochloride 
Molecular formula C31H33N5O4 
Molecular weight 539.6 g/mol 
Structure 
 
CAS No. 656247-17-5 
Description Nintedanib is a small molecule tyrosine-kinase inhibitor. It is a bright yellow crystalline powder. 
Melting point 244-251℃ 
Partition coefficient 3.0 
Solubility DMSO 25 mg/mL; Water <1 mg/mL 
Half life 10-15 hours 
Dosage Dose: 100 mg and 150 mg 




4.1.3  Galunisertib 
Galunisertib (LY2157299) is an oral small molecule experimental cancer drug in 
development by Eli Lilly. It is an inhibitor of the TGFβ receptor I (TGFβRI) kinase that 
specifically downregulates the phosphorylation of SMAD2, abolishing activation of the 
canonical pathway [103]. Galunisertib is currently under clinical development of various 
type of diseases such as glioma, hepatocellular carcinoma, pancreatic cancer and 
Myelodysplastic Syndromes [104]. Galunisertib showed a prominent antifibrotic potency 
in a human ex vivo model of liver fibrosis [105]. The profile of Galunisertib was outlined 
















Table 9. Galunisertib drug profile 
Name Galunisertib 
Chemical Name 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b] pyrazol-3-yl] quinoline-6-carboxamide 
Molecular formula C22H19N5O 
Molecular weight 369.42 g/mol 
Structure 
 
CAS No. 700874-72-2 
Description Galunisertib is an anti-fibrotic agent. It is a grey to brown solid powder. 
Solubility Water 0.0112 mg/mL 
LogP 3.11 
Polar Surface Area 86.69 Å2 
Half-life 8.6 h 
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4.1.4  Pirfenidone  
Pirfenidone is an orally administered drug with antifibrotic, anti-inflammatory, and 
antioxidant effects [106]. It approved by FDA on 2014 as a medication for the treatment 
of idiopathic pulmonary fibrosis under the brand name Esbriet [107]. In vitro evidence has 
shown that pirfenidone inhibits collagen synthesis, fibronectin synthesis, fibroblast, 
epidermal, platelet-derived, and transforming beta-1 growth factors, thereby slowing 
tumor cell proliferation [108-110]. Pirfenidone has demonstrated activity in various fibrotic 

















Table 10. Pirfenidone drug profile 
Name Pirfenidone 
Chemical Name 5-methyl-1-phenyl-1,2-dihydropyridin-2-one 
Molecular formula C12H11NO 
Molecular weight 185.22 g/mol 
Structure 
 
CAS No. 0053179-13-8 
Description Pirfenidone is potent TGFβ receptor I (TβRI) inhibitor. It is a white solid powder. 
Solubility Water 2.89 mg/mL 
Dosage forms Capsule, Tablet 





4.2  Materials  
ARV was obtained from ChemieTek (Indianapolis, IN, USA), Ni and Vemurafenib was 
purchased from LC Laboratories (Woburn, MA, USA), 1,2-Dioleoyl-sn-glycero-3 
phosphocholine (DOPC) was purchased from Cordenpharma (Liestal, Switzerland), PE 
18:0/18:0-PEG2000 was obtained from Lipoid (Ludwigshafen, Germany), Cholesterol 
and Chloroform were purchased from Sigma-Aldrich (MO, USA), The TGFβ1 ELISA 
kits were purchased from Invitrogen(Carlsbad, California, USA). Dulbecco's modified 
Eagle's medium (DMEM) was purchased from ThermoFisher Scientific Inc. (Waltham, 
MA, USA), Fetal Bovine Serum (FBS) was procured from Atlantic Biologics (Oakwood, 
GA, USA). Penicillin-Streptomycin-Amphotericin B (PSA) was purchased from MP 
Biomedicals, LLC (Solon, Ohio, USA).  MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide) was acquired from Fisher Scientific. Other chemicals and solvents 
were of analytical grade or chromatographic purity. 
 
Melanoma cell lines (A375 and Sk-Mel-28) were purchased from American Type Culture 
Collection (Manassas, Virginia, USA). Vemurafenib-resistant melanoma cell lines 
(A375R and SK-MEL-28R) was developed by adding vemurafenib to the cell line as the 
method described before (REF). The vemurafenib resistance was confirmed prior to 
studies. GFP expressing human dermal fibroblasts (HDFCs-adGFP) were obtained from 
angio-proteomie (Boston, MA, USA). Cells were cultured in DMEM medium 




4.3  Methods 
4.3.1  Analytical Method (HPLC method development) 
Chromatographic separation method of ARV and Ni was developed using Waters e2695 
separation module, equipped with 2998 Photo diode array (PDA) detector and Hypersil 
ODS C18 column (250mm ´ 4.6 mm, 5μm). The mobile phase was 
Acetonitrile:Potassium dihydrogen phosphate buffer (10 mM) of pH 3.5 (70:30) with a 
flow rate of 1 mL/min. The temperature of the column was kept at 25 °C and Empower 3 
software was used to monitor output signal. ARV was detected at 247 nm and Ni was 
detected at 390 nm. The retention time of ARV and Ni were 4.48 ± 0.02 min and 9.15 ± 















4.3.2  Enzyme Linked Immunosorbent Assay 
The enzyme linked immunosorbent assay (ELISA) kit was used to determine the level of 
TGF-β1 secreted by A375, SK-MEL-28, A375R and SK-MEL-28R and 3D spheroids. 
For 2D culture, cells were seeded at 1.2 × 104 cells per well in a 24-well plate and 
incubated at 37°C with 5% CO2. Cells were harvested when 90% confluency was reached. 
Then the supernatants were collected by centrifugation at 1,000 x g for 10 min at 4℃. 
For 3D spheroid culture, the supernatant in each well was taken on the 6th day before 
treatment. Three independent experiments were conducted in duplicate according to the 
manufacture’s protocol. Briefly, 100 μL of sample or TGF-β1 standard protein per well 
was incubated for 2 h at room temperature in ELISA plate that coated with capture 
antibody. Afterward, the samples were completely washed and 100 μL TGF-β1 detection 
antibody was added to each well for 1 h incubation followed by incubation with Avidin-
HRP and tetramethylbenzidine (TMB) substrate. Finally, after adding stop solution, the 
optical density (OD) values of different samples were detected at 450nm by using a 
microplate reader (Dynex Technologies). The concentration of TGF-β1 was interpolated 
using a second-order polynomial (quadratic) equation generated from a standard curve in 







4.3.3  Cell viability assay and effect of drug combination 
The cytotoxicity of ARV, Ni and ARNIPL were evaluated in A375R and SK-MEL-28R 
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. 
Logarithmic growth phase cells were seeded in 96-well plates at a density of 5000 
cells/well. After 24 h, drugs and formulation were diluted in cell culture medium to 
achieve different concentrations. After 48 h treatment, cells were incubated with 20 μL of 
5 mg/mL MTT solution in each well and incubated for 3 h at 37 °C, 5% CO2. Then the 
medium was removed and MTT-formazan crystals were dissolved by adding 100μL of 
dimethyl sulfoxide (DMSO) to each well. The quantity of MTT-formazan was 
determined by 570 nm absorbance on an Epoch2 microplate. IC50 were calculated using 
GraphPad Prism7 Software.  
Effect of ARV and Ni combination was assessed and according to Combination index 
(Chou-Talalay method) and Combenefit software (48). Following equation was used to 
calculating combination index (CI):  
CI = (D)1/(Dx)1+(D)2/(Dx)2                                                                                                          
where (Dx) 1, (Dx) 2 = the concentration of the tested substance 1 and the tested 
substance 2 used in the single treatment that was required to decrease the cell number by 
50% and (D) 1, (D) 2 = the concentration of the tested substance 1 in combination with 





4.3.4  Preparation of ARNIPL 
Modified hydration method was used for the preparation of ARNIPL. Briefly, ARV: Ni: 
DOPC: cholesterol: DSPE-PEG2000: citric acid in a 1:3.5:45:15:2 molar ratio was 
dissolved in chloroform. Parenteral-grade mannitol (200μm) was used as absorbent and 
the chloroform solution was drop-wise added to mannitol with constant stirring at 45ºC. 
The resultant paste was left overnight for chloroform evaporation. The resultant powder 
was dispersed in water contains citric acid at 55°C followed by sonication (30% 
amplitude) for 2 min. The same method was employed for the preparation of liposome 















4.3.5  Characterization of ARNIPL 
The average size, size distribution by intensity, zeta potential of ARNIPL were measured 
using dynamic light scattering (DLS) particle size analyzer (Malvern Zetasizer Nano ZS, 
Royston, UK). Samples were analyzed using disposable cuvettes at 25°C with a 
scattering angle of 173°. Amicon ultra centrifugal filters (50K) were used to analyze the 
entrapment efficiency of ARNIPL. The sample of total and free drug were collected and 
the concentration was analyzed by HPLC. The encapsulation efficiency was calculated 
using the following formula:  















4.3.6  Stability study  
ARNIPL prepared by modified hydration method were used for the stability study. 
Particle size, zeta potential, drug content and entrapment efficiency after one month of 
storage at 4 °C were evaluated. Samples were withdrawn at different time points after 
centrifugation of ARNIPL at 5000 rpm for 10min. The concentration of drug at each time 


















4.3.7  In Vitro Release Study  
Drug release from ARNIPL was carried out using the dialysis bag method. 
Dialysis bags (Spectra/Por® 7) were soaked in Milli-Q water at room temperature 
overnight to remove the preservative. Release of ARV and Ni were carried out at 37 °C 
in a dialysis sac with 100 mL of phosphate buffer saline (pH 7.4) containing 0.5% TPGS 
with constant stirring. The samples were withdrawn from the release medium at different 
time intervals up to 48 h. The concentration of ARV and Ni in the release media was 
















4.3.8 Clonogenic assay 
Clonogenic assay was carried out according to the procedure described previously (49). 
A375R were seeded at a density of 1000 cells/well in a 6-well plate. The cells were 
allowed to attach for around 5 h. Then the cells were treated with ARV (0.2 μM), Ni 
(0.7 μM) and ARNIPL (ARV 0.2 μM and Ni 0.7 μM) before the population doubling. 
The next day, the medium was replaced and cells were maintained at 37°C with 5% CO2 
for 5 days. Then cells were rinsed with PBS followed by glutaraldehyde (6.0% v/v) 
fixation and 0.5% crystal violet staining for 30 min. Thereafter, the plate was washed 
with water and left for drying. Colonies were counted (the colony is defined to consist of 
at least 50 cells) on the following day. Plating efficiency (PE) and survival fraction (SF) 
was calculated by following equations: 
PE = number of colony formed / number of cells seeded × 100%                                              










4.3.9  Vasculogenic mimicry 
A375R cells suspension at 2 × 105/ml were incubated with ARV (0.2 μM), Ni (0.7 μM) 
and ARNIPL (ARV 0.2 μM and Ni 0.7 μM) for 5 min at 37°C followed by seeding in a 
96 well plate precoated with 50 μL BME at a density of 2 × 104/well. After 24 h 
incubation at 37 °C with 5% CO2, images were taken using an EVOS light microscope at 


















4.3.10  Flow cytometry for apoptosis analysis  
A375R were seeded at a density of 1 ×105/mL in 6-well plate and cells were treated with 
ARV (1 μM), Ni (3.5 μM), ARNIPL (contains ARV 1 μM and 3.5 μM Ni) for 24 h 
incubation. Then cells were collected by centrifugation at 3000 rpm for 5 mins and 
resuspended with DMEM media (contains 1% bovine serum albumin and 1% FBS) to a 
concentration of 5 × 105 cells/mL. Apoptosis analysis was carried out by Muse Annexin 
V & Dead Cell Assay kit (Millipore Sigma, USA). Briefly, the cell suspension was 
diluted in 1:1 ratio with MUSE Annexin V dead cell reagent, followed by incubated for 
20 mins at room temperature, then the samples were analyzed for apoptosis using MuseÒ 














4.3.11  Determination of ARNIPL Efficacy in 3D Spheroids 
4.3.11.1  Development and characterization of 3D multicellular tumor spheroids 
Tumor spheroid of A375R alone and co-culture of A375R + dermal fibroblast (1:0.5) 
were prepared as follow; Briefly, cells were seeded at a density of 1500 cells/well in 
ultra-low attachment treated spheroid microplate (Corning Life Sciences, MA, USA). 
The plate was centrifuged at 150×g for 10 min and incubated overnight. The cells were 
then treated with ARV, Ni, ARNIPL and ARV+Ni with 1 μM ARV and 3.5 μM Ni in 
each group. Media was added as a control. The media was replaced with fresh treatment 
every alternative day until day 6. Moreover, same treatment groups with higher 
concentration (2 μM ARV and 7 μM Ni) were also investigated in co-culture spheroids 
and treated until day 4. Images of 3D spheroids were taken at 20× magnification every 
time before treatment using EVOS® FL Auto Imaging System (Thermo Fisher Scientific, 










4.3.11.2  3D cell viability study  
The viability of 3D spheroids was analyzed using CellTiter-Glo kit (Promega, Madison, 
WI, USA). After imaging on day 7 of treatments, equal volume of CellTiter-Glo® 
reagent was added in the well (100 μL of CellTiter-Glo® reagent and 100 μL of cell 
culture media in each well) and the plate was vigorously shaken for 5 minutes to induce 
cell lysis, followed by incubation at room temperature for 25 minutes to stabilize the 
luminescent signal. The luminescence was then measured using a Spark 10M plate reader 

















4.3.11.3  3D spheroid live & dead cell imaging 
On the 7th day of treatment, spheroids were washed twice with phosphate-buffered saline 
(PBS) followed by staining with 3 μM EthD-1 and 1μg/mL DAPI (Santa Cruz 
Biotechnology, TX, USA) in PBS solution. The plate was incubated at 37°C for 3 h and 
fluorescent images were then taken at 20× using EVOS-FL Cell Imaging fluorescence 


















4.4  Results and Discussion 
4.4.1  Analytical Method (HPLC) 
 
 




Figure 14. Standard curve of Ni.
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4.4.2  Enzyme Linked Immunosorbent Assay 
In order to investigate whether TGF-β1 production is more in the vemurafenib-resistant 
melanoma cells than BRAFV600E mutated melanoma cell lines, two BRAFV600E mutated 
melanoma cell lines A375 and SK-MEL-28 and their vemurafenib-resistant cells lines 
were used in ELISA assay to compare the amount of TGF-β1 release from the same 
number of cells. The result shown in Figure 15 revealed that a significant increasing 
amount TGF-β1 was found in the vemurafenib-resistant cell lines, which suggested the 

















Figure 15. ELISA analysis of TGFβ1 produced by BRAFV600E mutated melanoma cell 
lines and its vemurafenib-resistant cell lines. Results are expressed as the amount 
(pg)/mL of TGFβ1 produced by the same number of cells of (a) A375 and A375R, (b) 





4.4.3  Cell viability assay and effect of drug combination 
 The effect of drug combination was analyzed using Combenefit software.  The contour 
plot of synergy/antagonism with the Bliss model was shown in Figure 16. The positive 
scores mean the drug combination are synergistic while the negative scores indicated the 
combination was antagonist. All positive scores were observed in A375R while in SK-
MEL-28R, the scores are less with lighter blue color. The result suggested that the 
synergistic effect was stronger of ARV and Ni in A375R compared with SK-MEL-28R. 
Thus, the further anti-cancer efficacy studies of ARNIPL were evaluated in A375R. As 
shown in Figure 17, Free Ni and ARNIPL killed cells in dose-dependent manners. 
However, ARV did not show further killing above 1μM, which can be explained by 
“hook effect” and resulted in a bell-shaped dose-response curve of the PROTAC 
molecules. This phenomenon is attributed to the mechanism of the PROTAC molecule, 
which tends to form a binary complex with either E3 ligase or protein of interest instead 
of forming ternary complex at higher concentration [112]. Nevertheless, the combination 
of Ni with ARV may not only serve a dual-functional targeting purpose, but also alleviate 
the limitation of “hook effect”. On the other side, ARV dominate the killing at very low 
concentration while Ni did not show too much killing. However, with the increasing of 
concentration, Ni showed promising killing of melanoma cells and the combination with 
ARV in ARNIPL further decrease the viability. Additionally, the IC50 of ARV and Ni in 
the liposomes were lower than the free drug (Table 11). The calculated combination 
index (CI) of ARV and Ni was 0.54 ± 0.05 while the CI of ARNIPL showed 0.59 ± 0.12, 






Figure 16. Combenefit mapped surface output for the drug combinations involving ARV 
and Ni using Bliss synergy model. ARV and Ni synergistically inhibit cell growth in a 
panel of (a) A375R and (b)SK-MEL-28R. Cells were treated with ARV and Ni in a 5x5 
concentration grid for 48 h, cell viability was determined by MTT assay. The darker the 





Figure 17. Cytotoxicity assay of ARV, Ni and ARNIPL in A375R. (a) % Cell viability 
with ARV, Ni and ARNIPL treatment in A375R. (b) The % viability comparison of ARV, 
Ni and ARNIPL at various concentrations. Data was plotted as mean ± SEM (n=3). 
 
Table 11. In vitro cytotoxicity of Ni, ARV alone and in the liposomes in A375R (n=3). 
Drug Ni ARV ARNIPL-Ni ARNIPL-ARV 






4.4.4  Characterization 
Due to the poor entrapment efficiency (EE) and drug loading (DL) of ARV and Ni, citric 
acid was incorporated in the hydration step to enhance the EE and DL via interaction of 
citric acid with basic drugs. Weak acids or weak bases are used in the formulation 
development for solubility and stability enhancement. Due to the basic property of the 
drugs, we selected citric acid due to its safe use in parenteral delivery. Initially, 1% ARV 
and 2% Ni were aiming to loaded into the liposomes, the EE without critic acid of ARV 
and Ni were 79.68%, 21.67% respectively, while result in more than 90% EE of both of 
the drugs with the citric acid. Moreover, the DL of ARV and Ni was also increased with 
citric acid (Table 12).  Thereafter, we prepared batches with high DL and high 
concentration of ARV and Ni. The particle size and zeta potential of optimized ARNIPL 
are shown in Figure 18, the mean particle size of ARNIPL is 111.1 ± 6.97 nm, which is in 
the range of enhanced and permeation (EPR) effect that allows particles to easily 
extravasate into tumors. The polydispersity index was less than 0.3, which indicates the 
particles were uniformly distributed. The zeta potential of ARNIPL was found to be 
+13.9 ± 6.62, which may mainly attribute to the orientation of basic (amine group) 
towards surface of ARNIPL with lipophilic part entangled in lipid bilayer. This 
arrangement is similar to the cholesterol in the membrane, where eight-carbon branched 
aliphatic tail located in the membrane whereas the polar hydroxyl group was left outside 
[113]. Moreover, the head group-modified lipids with amine is also exposed on the outside 





Table 12. Particle size, zeta potential and entrapment efficiency (EE) of ARNIPL (n=3). 
 
Group              Size            Zeta potential         EE of ARV(%)         EE of Ni(%)     DL of ARV(%)      DL of Ni(%)                                                                                    
                         (nm)                      (mV)           
 
ARNIPL       138.4 ± 6.66        -25.2 ± 4.41         79.68 ± 7.60         21.67 ± 2.15          0.80 ± 0.08            0.43 ± 0.04 
(without citric acid) 
 ARNIPL      99.62 ± 4.78.      -5.34 ± 3.82          94.15 ± 3.48         97.16 ± 2.33         0.94 ± 0.03            1.94 ± 0.05 
(with citric acid) 




Figure 18. ARNIPL characterization. (a) Particle size distribution with an average 






4.4.5  Stability study 
Physical stability of ARNIPL prepared by modified hydration method was analyzed after 
a month storage at 4°C. ARNIPL was found to be physical stable for one month at 4°C 
storage (Figure 19 (a)), which indicated the ARNIPL was stable after a month storage. 
Moreover, the particle size of ARNIPL was 111.5 ± 6.55 with polymer dispersity index 

















Figure 19. The stability result of ARNIPL. (a) Drug content after a month storage at 4°C. 
The data of each time point was conducted in triplicate and was shown as mean with 














4.4.6   In Vitro Release Study 
The release of ARNIPL was detected by HPLC at 1 h, 2 h, 4 h, 6 h, 8h, 24h and 48 h. 
Sink condition was maintained during the study using a non-ionic surfactant 0.5% TPGS 
in the release medium. The result showed less 2% of ARV and less than 5% of Ni was 
released in 24 h. After 48 h, the percentage release of both drugs was increased but still 
within 5% for ARV and less than 10% for Ni at sink conditions (Figure 20), which 
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Figure 20. In vitro release study of ARNIPL. Release of ARV and Ni were observed at 









4.4.7  Clonogenic assay 
The ability to form colonies after treatment was analyzed by clonogenic assay, which also 
determines cell reproductive death after treatment. Results as shown in Figure 21 
suggested that the number of colonies were significantly reduced by the exposure to Ni 
and ARV alone group. ARNIPIL showed 8-20 folds lesser number of colonies compared 
to drug alone and control group. Plating efficiency (PE) of A375R control was 40 %. 
Survival fraction (SF) of ARNIPL was much lower compared to other treatment groups 
as shown in Table 13. ARNIPL exhibited more predominant inhibition of melanoma cells 
to form colonies, which is in accordance with our cytotoxicity suggesting that the 
combination of drugs exerted synergistic effect in melanoma tumor inhibition. Moreover, 
TGF-β1 was found to related with regulating clonogenicity of melanoma cells and TGF-
β1 inhibition could block the clonogenicity through SMAD4-independent inhibition of 

















Figure 21. Colony forming ability of A375R after treatment with ARV, Ni and ARNIPL 
(a) Crystal violet staining images of A375R after various treatments. (b) Number of 
colonies with ARV, Ni and ARNIPL treatment and control in A375R. Number of 
colonies with ARNIPL treatment were significantly reduced compared to other groups 












Table 13. Clonogenic Assay: Surviving Fraction (SF) of treatment cells 
(n = 3); S.D. = Standard deviation. 
%SF ± S.D. Ni ARV ARNIPL 





















4.4.8  Vasculogenic mimicry 
Melanoma vasculogenic mimicry was first described and characterized by Maniotis 
group, where the tube formation was distinct from endothelial cells [116]. Vasculogenic 
mimicry is a different vascular formation mechanism compared to traditional 
angiogenesis, which is formed by tumor cells and independent of endothelial cells. The 
tube formation by vasculogenic mimicry that observed in aggressive tumors provides 
sufficient blood perfusion and nutrition to the tumor, which is related to the poor survival 
[117]. The formation of vasculogenic mimicry was observed in A375R on the Matrigel. 
ARV and Ni inhibited vasculogenic mimicry at very low concentration as shown in 
Figure 22 (a). ARNIPL containing ARV and Ni showed further inhibition of 
vasculogenic mimicry compared to each individual drug. The number of branching points 
are plotted in Figure 22 (b), where ARV and ARNIPL both showed most significantly 
lower number of branching points. There was no statistically significant difference 
between ARV and ARNIPL. We previously demonstrated that ARV has promising effect 
in the inhibition of vasculogenic mimicry in A375R [118]. In the present paper, Ni was 
also able to inhibit vasculogenic mimicry. This may be due to inhibition of multiple 
signaling pathway, which was reported to be a potential target for anti-vasculogenic 
mimicry in cancer [119]. ARNIPL displayed the most predominant anti-vasculogenic 









Figure 22. Evaluating the effect of ARNIPL on A375R vasculogenic mimicry (a) 
Vasculogenic mimicry images of A375R treated with ARV (0.2 μM), Ni (0.7 μM) and 
ARNIPL (ARV 0.2 μM and Ni 0.7 μM). (b) Number of branching points after treated 
with ARV, Ni and ARNIPL treatment in A375R. Data were expressed as mean ± S.D. 
ARNIPL shows significantly less number of branching points compared to other 





4.4.9 Apoptosis assay 
Apoptosis of vemurafenib-resistant melanoma cell line A375R was carried out by flow 
cytometry, which shows percentage of early and late apoptosis distribution of the treated 
cells. The total apoptosis was calculated as the sum of early apoptosis and late apoptosis. 
Total apoptosis of Ni, ARV, ARNIPL and ARV+Ni is shown in Figure 23, where 
ARNIPL and the combination of ARV and Ni showed significantly higher amount of 
apoptosis compared to ARV and Ni alone. As expected, there was no difference in 
number of apoptotic cells in ARV+Ni (Added from DMSO stock) and ARNIPL (Same 
concentration added as liposomal formulation). As for the result of apoptosis assay, 
ARNIPL and ARV+Ni groups showed higher population of early/late apoptosis 
compared to single ARV or Ni treatment. The apoptotic effect of ARV was reported as a 








Figure 23. Flow cytometric analysis in A375R treated with 3.5 μM Ni, 1 μM ARV, 
ARNIPL and ARV+Ni (3.5 μM Ni and 1 μM ARV) after 24 h treatment, ARNIPL 














4.4.10 Determination of ARNIPL Efficacy in 3D Spheroids 
4.4.10.1 Development and characterization of 3D multicellular tumor spheroids 
In order to better mimic in vivo tumor growth, 3D multicellular tumor spheroids of 
A375R and co-culture spheroids with dermal fibroblasts were developed to evaluate the 
efficacy of ARNIPL. According to the bright field images of A375R and co-culture 
spheroids with different treatments on days 0, 2, 4, and 6 as shown in Figure 24 (a) and 
(b), the growth of co-culture spheroids was found to be much faster than the spheroids 
that only contains A375R. The spheroid growth-promoting effect from fibroblasts co-
culture has previously been discussed due to the role of fibroblasts in tumor progression 
[123]. The reduction of tumor spheroids with Ni and ARV at low concentration suggested 
the drugs are very potent. Moreover, the killing pattern of ARV and Ni observed from the 
surface of the spheroids was different. The killing effect of ARV can be observed on the 
surface, as seen from the irregular surface of the spheroids on day 6, which means ARV 
inhibits tumor growth by killing melanoma cells from the surface. As for the Ni treatment, 
the spheroids surface remains regular round shape and showed more intact smooth 
surface while the tumor growth has been inhibited, which implied the growth inhibition 
could be related with the regulation of melanoma cells through various signaling 
pathways. For instance, Ni could inhibit multiple factors and reduce CAFs through TGF-
β1 inhibition, which affects the proliferation of melanoma cells. Ni treated groups also 
showed dark and dense core, which may be due to the apoptotic cells present on the 
periphery of the spheroids [124]. The surface of combination of spheroids treated with 
both drugs in ARNIPL and ARV+Ni was uneven and showed better inhibition in tumor 
volume compared to individual drugs, this further confirmed the importance of drug 
 
 98 
combination and could be related with synergistic effect of ARV and Ni. As for A375R 
spheroids growth as a function of time (Figure 24 (c)), Control and Ni group exhibited 
constant growth till day 6 and Ni showed slower growth compared to control. ARV, 
ARNIPL and ARV+Ni treated groups showed substantial inhibition of tumor growth 
compared with control. The volume of A375R spheroids with various treatments were 
compared on day 6 as shown in Figure 24 (e), all the treatment groups showed significant 
tumor volume reduction compared with control. Precisely, ARV treated group displayed 
more reduction of tumor volume than Ni treated group, and the combination of both 
drugs in ARNIPL and ARV+Ni further decreased the volume of the spheroids. Moreover, 
ARNIPL treated groups presented lower tumor volume compared with ARV+Ni, which 
may be due to the better penetration of the liposomes. The reduction of volume with 
ARV, Ni, ARNIPL and ARV+Ni treatment compared to control were 41.34%, 9.60%, 
51.71% and 36.19%, respectively. The volume of the co-culture spheroids with various 
treatments as a function of time were shown in Figure 24 (d), spheroids showed rapid 
growth in control and Ni treated groups while other treatment groups showed significant 
inhibition in terms of tumor growth. The tumor volume of various treatments was 
compared at day 6 as shown in Figure 24 (f) where all the groups showed significant 
tumor inhibition compared with control. On day 6, The reduction of volume with ARV, 
Ni, ARNIPL and ARV+Ni treatment compared to control are 57.14%, 7.14%, 71.43% 
and 71.43%, respectively. ARV treated group exhibited more inhibition than Ni treated 
group in terms of tumor volume. And the combination group of drugs in ARNIPL and 
ARV+Ni showed further reduction of tumor volume compared to individual drugs. No 
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significant difference in tumor volume was observed in ARNIPL compared to ARV+Ni 





Figure 24. The effect of various treatments on A375R and A375R+Dermal Fibroblast co-
culture 3D multicellular tumor spheroids growth. Spheroids were treated with control, 1 
μM ARV, 3.5 μM Ni, ARNIPL and ARV+Ni (1 μM ARV and 3.5 μM Ni) (a) Bright 
field images of A375R spheroids with treatments on days 0, 2, 4, and 6. (b) Bright field 
images of co-culture spheroids with treatments on days 0, 2, 4, and 6. (c) Comparison of 
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the volume of A375R spheroids. (e) Comparison of the volume of co-culture spheroids 
with various treatments at day 0, 4 and 6. (f) The volume of A375R spheroids on day 6. (f)  
The volume of co-culture spheroids on day 6.   Significant difference in volume of 
spheroids was observed with ARV, Ni, ARNIPL and ARV+Ni compared to control. (**p 
< 0.01, ***p< 0.001, ****p< 0.0001).
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4.4.10.2 3D cell viability study  
The CellTiter-Glo luminescent cell viability assay was performed to study the number of 
viable cells in treated A375R and co-culture spheroids on day 7. ARNIPL and ARV+Ni 
exhibited a significantly reduced number of alive cells compared to control, Ni and ARV 
(Figure 25). Moreover, Ni also showed decreased cell viability in co-culture spheroids 



















Figure 25. 3D cell viability assay conducted using CellTiter-Glo® kit. Results of various 
treatments in (a) A375R and (b) Co-culture 3D spheroids are shown as relative 








4.4.10.3   3D spheroid live & dead cell imaging 
The fluorescent images of the dead cells and nuclei were taken on day 7. The red 
fluorescence obtained from ethidium homodimer-1 represents dead cells in the spheroids 
while blue color stained by DAPI represent cell nuclei. Green fluorescence was shown by 
GFP-labeled fibroblasts. Figure 26 showed the spheroids treated with ARV, ARNIPL and 
ARV+Ni had higher red intensity compared to control and Ni group. ARV and ARNIPL 
treated groups exhibited stronger red fluorescent intensity indicating higher killing of 
melanoma cells. In the co-culture model, the green fluorescent signal can be observed on 
the surface of the spheroids with Ni treatment whereas other groups showed faint green 
fluorescence and cannot be seen clearly after merging. This could be attribute to the 
inhibition growth of melanoma cells with Ni treatment. Similarly, ARV+Ni treated group 
also showed some extent green fluorescence on the surface of the spheroids. ARV, 
ARNIPL and ARV+Ni treated groups showed strong red intensity representing the dead 
cells. Moreover, the spheroids size of control is the largest, however, only the center that 
stained with nuclei dye can be seen, whereas spheroids with Ni treatment showed green 
fluorescence on the whole surface of the spheroids. This may due to the aggressive 
growth of melanoma cells were covered by the fibroblasts in the control group, on the 
other side, melanoma cells could be inhibited with Ni treatment so that the fluorescent 








Figure 26. A375R and coculture 3D spheroids live & dead cell imaging on day 6. 
Spheroids were stained with DAPI (blue) for nuclei, EthD-1 (red) for compromised/dead 
cells, green fluorescence was shown by GFP-labeled fibroblasts. Representative images 






5  Limitations 
The main objective is to develop nanoliposomes for the treatment of BRAF-mutant 
metastatic melanoma. In the first part of the thesis, active targeting PEGylated 
nanoliposomes (YTPL) were developed to target overexpressed EphA2 receptor in 
melanoma cell lines. However, we observed that expression of EphA2 receptor is 
relatively low in Vem resistant melanoma and uptake of YTPL was also lower in resistant 
melanoma cell compared to parent cells. Thus, YSA targeted liposomes could be helpful 
in melanoma but not in Vem resistant melanoma. Moreover, Vem resistant melanoma is 
also cross-resistance to MEK inhibitor. In second part we investigated effect of 
combination of a novel PROTAC molecule ARV-825 and anti-fibrotic agent Nintedanib 
in Vem resistant melanoma. Further, a nanoliposomes of ARV and NIN (ARNIPL) was 
developed, characterized and tested using various cytotoxicity assay.  Nevertheless, there 
are some limitations as following: 
• ARNIPL was found to be stable for one month in liquid form, however, the long-term 
stability could not be possible without freeze drying.   
• Stroma-targeting strategy is helpful to enhance the uptake of therapeutics; however, it 
could be unpredictable whether modulating the ECM and stromal components of solid 
tumors will promote tumor metastasis and progression. Further in-vivo study and more 
considerations like administration time, sequence need to be investigated to achieve 
therapeutic benefit. 
• PROTACs showed Hook effect at a higher concentration and it may eliminate the 
targeted protein sub-stoichiometrically. Additionally, Ni showed therapeutic effect only 
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above certain concentration. Thus, dose determination of is crucial and need to be 
thoroughly explored. 
• There is possibility that melanoma cell become resistant to ARV and/or Ni similar to 
Vem therapy. We might evaluate it in future.  
• The mechanism and the effect of Ni and ARV on fibroblasts in the 3D spheroids need to 




















6  Summary 
EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF 
V600E Mutated Parent and Resistant Melanoma  
As per our published work [125]. 
• Modified hydration showed higher entrapment efficiency of TMB than traditional thin 
film hydration method. 
• The stability of TPL was enhanced using 10% trehalose as a cryoprotectant in the freeze 
drying. 
• Differential scanning calorimetry (DSC) study confirmed that TMB was retained in a 
solubilized state within lipid bilayers.  
• The drug release study showed TPL did not leak or burst release in 24 h.  
• The hemolysis observed was negligible at therapeutic concentrations of TMB.  
• Liposome showed higher intracellular uptake in parental cell lines compared to 
vemurafenib-resistant cell lines. 
• Western blot analysis and a cytotoxicity study with the EphA2 inhibitor confirmed a 
reduction in EphA2 expression in resistant cell lines. 
 
Thus, EphA2 receptor-targeted nanoliposomes can be useful for metastatic melanoma-
specific delivery of TMB. 
 
 109 
Development of Dual ARV-825 and Nintedanib - Loaded Nano-liposome for 
synergistic efficacy in Vemurafenib-resistant Melanoma 
 
• A significant increasing amount TGF-β1 was found in the vemurafenib-resistant 
melanoma cell lines compared to melanoma cell lines, which suggested the potential of 
targeting TGFβ1 in vemurafenib-resistant melanoma 
• PROTAC molecule ARV and anti-fibrotic agent Ni exhibited synergistically in killing 
resistant melanoma cells. ARNIPL also remain the similar synergistic of cytotoxicity in 
resistant melanoma cells  
• Entrapment efficiency, drug loading and stability of ARV and Ni in the ARNIPL were 
enhanced with the incorporation of citric acid. 
• The drug release study showed ARNIPL did not leak or burst release in 48 h.  
• ARNIPL showed significant higher population of early/late apoptosis after 24h treatment. 
• ARNIPL demonstrated significant inhibition of vasculogenic mimicry and clonogenic 
effect in A375R. 
• 3D multicellular tumor spheroids showed ARNIPL has promising inhibition effect in 
terms of tumor growth. 
 
Hence, ARNIPL has encouraging indication for the treatment of vemurafenib-resistant 






7 Significance and future perspectives 
This thesis provides two potential therapeutic approach for the treatment of BRAF-
mutant metastatic melanoma. The first perspective is based on the current problems of 
associated with MEK inhibitor based targeted therapy. In order to minimize the side 
effects of MEKi trametinib, active targeting PEGylated nanoliposomes YTPL were 
successfully developed by leveraging both passive targeting and active targeting of 
nanoliposomes. Moreover, considering the reduced EphA2 expression in vemurafenib-
resistant cell lines as well as cross-resistance to the MEKi, the second perspective focuses 
on exploring novel drug combinations using PROTAC molecule ARV-825 and anti-
fibrotic agent Nintedanib, PROTAC molecule ARV. The combination effect of ARV and 
Ni was investigated for the first time in vemurafenib-resistant melanoma. ARNIPL was 
successfully developed using modified hydration method, where ARV and Ni exhibited 
synergism in killing vemurafenib-resistant melanoma cells in-vitro and strong tumor-
suppressive effect in 3D spheroid model. Considering the importance and promising 
outcomes of this thesis, the following points could be done for the future research: 
• Molecular mechanism behind ARV and Ni synergism  
• Possibility of resistance development to ARV and Ni treatment 
• Freeze-drying of ARNIPL 
• Anticancer efficacy testing of ARNIPL in vemurafenib-resistant melanoma tumor 
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